Reviva Pharmaceuticals (RVPH) to Release Quarterly Earnings on Monday

Reviva Pharmaceuticals (NASDAQ:RVPH) will likely be releasing its earnings data before the market opens on Monday, April 14th. Analysts expect Reviva Pharmaceuticals to post earnings of ($0.22) per share for the quarter.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. On average, analysts expect Reviva Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Reviva Pharmaceuticals Stock Performance

NASDAQ:RVPH opened at $0.53 on Monday. The stock has a 50-day simple moving average of $1.40 and a 200 day simple moving average of $1.45. Reviva Pharmaceuticals has a 52-week low of $0.49 and a 52-week high of $4.28. The company has a market cap of $17.72 million, a PE ratio of -0.48 and a beta of 0.05.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RVPH shares. Roth Mkm began coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. D. Boral Capital cut their price target on shares of Reviva Pharmaceuticals from $15.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, January 10th. Finally, HC Wainwright dropped their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Reviva Pharmaceuticals has a consensus rating of “Buy” and an average target price of $10.00.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.